SCLC Tarlatamab Blood Collection

Starting soon

Conditions studied: Small-cell Lung Cancer

In brief

The overall objective of this project is to prospectively collect blood samples throughout treatment with tarlatamab in patients with small cell lung cancer (SCLC). These samples will then be analyzed through a variety of assays to better characterize tarlatamab in the real-world setting. The investigators will prospectively collect blood samples from 25 patients on days 1, 8, and 15 of tarlatamab treatment, as well as after each interval scan for disease monitoring. The investigators will also collect patient data including demographics and baseline characteristics, primary diagnosis, treatment history, and disease monitoring and progression.

Key facts

Study ID

NCT07468656

Run by

Duke University

People needed

25

Starts

2026-10-01

Expected to finish

2028-12-01

Last updated by the study team

2026-08-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathologically documented small cell lung cancer (SCLC) or neuroendocrine tumor
• Appropriate candidate for treatment with tarlatamab based on investigator discretion
• Age > 18 years
• Signed written informed consent including HIPAA according to institutional guidelines

You may not qualify if…

• Does not meet all inclusion criteria

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.